Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer
Crossref DOI link: https://doi.org/10.1007/s00280-017-3438-y
Published Online: 2017-10-17
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lenz, Heinz-Josef http://orcid.org/0000-0003-2178-9568
Philip, Philip
Saunders, Mark
Kolevska, Tatjana
Mukherjee, Kalyan
Samuel, Leslie
Bondarde, Shailesh
Dobbs, Tracy
Tagliaferri, Mary
Hoch, Ute
Hannah, Alison L.
Berkowitz, Maurice
License valid from 2017-10-17